European Spine Journal

, Volume 16, Issue 8, pp 1257–1265 | Cite as

Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2

  • Rahul Vaidya
  • Julia Carp
  • Anil Sethi
  • Stephen Bartol
  • Joseph Craig
  • Clifford M. Les
Original Article


The use of bone morphogenetic protein-2 (rhBMP-2) in spinal fusion has increased dramatically since an FDA approval for its use in anterior lumbar fusion with the LT cage. There are several reports of its use in transforaminal lumbar interbody fusion, posterolateral fusion, and anterior cervical fusion. Reports on adverse effects of rhBMP-2 when used in spinal fusion are scarce in literature. An Institutional Review Board approved retrospective study was conducted in patients undergoing anterior spinal fusion and instrumentation following diskectomy at a single center. Forty-six consecutive patients were included. Twenty-two patients treated with rhBMP-2 and PEEK cages were compared to 24 in whom allograft spacers and demineralized bone matrix was used. Patients filled out Cervical Oswestry Scores, VAS for arm pain, neck pain, and had radiographs preoperatively as well at every follow up visit. Radiographic examination following surgery revealed end plate resorption in all patients in whom rhBMP-2 was used. This was followed by a period of new bone formation commencing at 6 weeks. In contrast, allograft patients showed a progressive blurring of end plate-allograft junction. Dysphagia was a common complication and it was significantly more frequent and more severe in patients in whom rhBMP-2 was used. Post operative swelling anterior to the vertebral body on lateral cervical spine X-ray was significantly larger in the rhBMP-2 group when measured from 1 to 6 weeks after which it was similar. These effects are possibly due to an early inflammatory response to rhBMP-2 and were observed to be dose related. With the parameters we used, there was no significant difference in the clinical outcome of patients in the two groups at 2 years. The cost of implants in patients treated with rhBMP-2 and PEEK spacers was more than three times the cost of allograft spacers and demineralized bone matrix in 1, 2, and 3-level cases. Despite providing consistently good fusion rates, we have abandoned using rhBMP-2 and PEEK cages for anterior cervical fusion, due to the side effects, high cost, and the availability of a suitable alternative.


Bone morphogenetic protein-2 Cage Anterior cervical fusion Allograft bone 


  1. 1.
    A guide from the The American Academy of Orthopedic Surgeons (AAOS) and American Association of Tissue Banks (AATB): What can you tell me about bone and tissue transplantation. Retrieved June 21, 2005 from
  2. 2.
    Baskin DS, Ryan P, Sonntag V, Westmark R, Widmayer MA (2003) A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SRTM allograft ring and the ATLANTISTM anterior cervical plate. Spine 28(12):1219–1224PubMedCrossRefGoogle Scholar
  3. 3.
    Boakye M, Mummaneni PV, Garrett M, Rodts G, Haid R (2005) Anterior cervical discectomy and fusion involving a polyetheretherketone spacer and bone morphogenetic protein. J Neurosurg Spine 2:521–525PubMedGoogle Scholar
  4. 4.
    Boden SD, Kang J, Sandhu H, Heller JG (2002) Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, Randomized clinical pilot trial 2002 Volvo Award in clinical studies. Spine 27(23):2662–2673PubMedCrossRefGoogle Scholar
  5. 5.
    Burkus JK (2004) Bone morphogenetic proteins in anterior lumbar interbody fusion: old techniques and new technologies. J Neurosurg Spine 3:254–260Google Scholar
  6. 6.
    Burkus JK, Heim SE, Gornet MF, Zdeblick TA (2004) The effectiveness of rhBMP-2 in replacing autograft: an integrated analysis of three human spine studies. Orthopedics 27(7):723–728PubMedGoogle Scholar
  7. 7.
    Celeste AJ, Iannazzi JA, Taylor RC, Hewick RM, Rosen V, Wang EA, Wozney JM (1990) Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. Proc Natl Acad Sci USA 87(24):9843–9847PubMedCrossRefGoogle Scholar
  8. 8.
    Hidehiro I, Sohei E, Mikio K, Yutaka T, Tetsuya K, Yohei Y, Kunio T (1999) Experimental spinal fusion with use of recombinant human bone morphogenetic protein 2. Spine 24(14):1402–1405CrossRefGoogle Scholar
  9. 9.
    Johnson EE, Urist MR, Finerman GAM (1988) Bone morphogenetic protein augmentation grafting of resistant femoral nonunions. A preliminary report. Clin Orthop Relat Res 230:257–265PubMedGoogle Scholar
  10. 10.
    Johnson EE, Urist MR, Finerman GA (1988) Repair of segmental defects of the tibia with cancellous bone grafts augmented with human bone morphogenetic protein. A preliminary report. Clin Orthop Relat Res 236:249–257PubMedGoogle Scholar
  11. 11.
    Kleeman TJ, Michael Ahn U, Talbot-Kleeman A (2001) Laparoscopic anterior lumbar interbody fusion with rhBMP-2: a prospective study of clinical and radiographic outcomes. Spine 26(24):2751–2756PubMedCrossRefGoogle Scholar
  12. 12.
    Mummaneni PV, Pan J, Haid RW, Rodts GE (2004) Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion. J Neurosurg Spine 1:19–23PubMedCrossRefGoogle Scholar
  13. 13.
    Poynton AR, Lane JM (2002) Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine 27(16S):S40–S48PubMedCrossRefGoogle Scholar
  14. 14.
    Sandhu HS (2003). Bone morphogenetic proteins and spinal surgery. Spine 28(15S):S64–S73PubMedCrossRefGoogle Scholar
  15. 15.
    Sandhu HS, Khan SN (2003) Recombinant human bone morphogenetic protein-2: use in spinal fusion applications. J Bone Joint Surg 85-A(Suppl 3):89–95PubMedGoogle Scholar
  16. 16.
    Sandhu HS, Toth JM, Diwan AD, Seim HB, Kanim LEA, Kabo JM, Turner AS (2002) Histologic evaluation of the efficacy of rhBMP-2 compared with autograft bone in sheep spinal anterior interbody fusion. Spine 27(6):567–575PubMedCrossRefGoogle Scholar
  17. 17.
    Schimandle JH, Boden SD, Hutton WC (1995) Experimental spinal fusion with recombinant human bone morphogenetic protein-2. Spine 20(12):1326–1337PubMedCrossRefGoogle Scholar
  18. 18.
    Shields LB, Raque GH, Glassman SD, Campbell M, Vitaz T, Harpring J, Shields CB (2006) Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 31(5):542–547PubMedCrossRefGoogle Scholar
  19. 19.
    Ullrich PF (1999) Anterior cervical spinal fusion surgery. Retrieved June 21, 2005 from
  20. 20.
    Urist MR (1965) Bone: formation by autoinduction. Science 150:893–899PubMedCrossRefGoogle Scholar
  21. 21.
    Wang EA, Rosen V, D’Alessandro JS, Bauduy M, Cordes P, Harada T, Israel DI, Hewick RM, Kerns KM, LaPan P et al (1990) Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci USA 87(6):2220–2224PubMedCrossRefGoogle Scholar
  22. 22.
    Wang EA, Rosen V, Cordes P, Hewick RM, Kriz MJ, Luxenberg DP, Sibley BS, Wozney JM (1988) Purification and characterization of other distinct bone-inducing factors. Proc Natl Acad Sci USA 85(24):9484–9488PubMedCrossRefGoogle Scholar
  23. 23.
    Zdeblick TA, Ghanayem AJ, Rapoff AJ, Swain C, Bassett T, Cooke ME, Markel M (1998) Cervical interbody fusion cages: an animal model with and without bone morphogenetic protein. Spine 23(7):758–765PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Rahul Vaidya
    • 1
  • Julia Carp
    • 2
  • Anil Sethi
    • 1
  • Stephen Bartol
    • 2
  • Joseph Craig
    • 3
  • Clifford M. Les
    • 2
  1. 1.Department of OrthopedicsDetroit Receiving Hospital, University Health CenterDetroitUSA
  2. 2.Department of Orthopedics Henry Ford HospitalDetroitUSA
  3. 3.Department of Radiology Henry Ford HospitalDetroitUSA

Personalised recommendations